G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for Small Cell Lung Cancer in the US and Puerto Rico
Shots:
- Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally- it receives mid-twenties percentage of net sales in the 1st yr. of commercialization- which decreases to a low double-digit/high single-digit percentage in the 2nd and 3rd year respectively
- G1 will book revenue in the selective territories and retain global development and commercialization rights to Trilaciclib. In the US and Puerto Rico- G1 will lead marketing- market access- and medical engagement initiatives while Boehringer will control salesforce engagements
- G1 will not make any payments after the expiration of 3yrs. agreement and does not extend the agreement to additional indications for the therapy. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with CT and has received the FDA’s BT designation and has submitted NDA for SCLC in Jun’2020
Click here to read full press release/ article | Ref: Buisnesswire | Image: Boehringer Ingelheim
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
